COVID-19 and hypertension: Is there a role for dsRNA and activation of Toll-like receptor 3?

Vanessa Dela Justina, Fernanda R Giachini, Fernanda Priviero, R Clinton Webb
Author Information
  1. Vanessa Dela Justina: Graduate Program in Biological Sciences, Federal University of Goiás, Goiânia, Brazil. Electronic address: vane_cessa@hotmail.com.
  2. Fernanda R Giachini: Graduate Program in Biological Sciences, Federal University of Goiás, Goiânia, Brazil; Institute of Health Sciences and Health, Universidad Federal De Mato Grosso, Barra Do Garcas, Brazil.
  3. Fernanda Priviero: Cardiovascular Translational Research Center - School of Medicine, University of South Carolina, Columbia, SC, United States.
  4. R Clinton Webb: Cardiovascular Translational Research Center - School of Medicine, University of South Carolina, Columbia, SC, United States.

Abstract

The virus responsible for the coronavirus disease of 2019 (COVID-19) is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Evidences suggest that COVID-19 could trigger cardiovascular complications in apparently healthy patients. Coronaviruses are enveloped positive-strand RNA viruses acting as a pathogen-associated molecular pattern (PAMP)/ danger-associated molecular patterns (DAMP). Interestingly, Toll-like receptor (TLR) 3 recognize both PAMPs DAMPs and is activated by viral double-stranded RNA (dsRNA) leading to activation of TIR receptor domain-containing adaptor inducing IFN-β (TRIF) dependent pathway. New evidence has shown a link between virus dsRNA and increased BP. Hence, we hypothesize that COVID-19 infection may be over activating the TLR3 through dsRNA, evoking further damage to the patients, leading to vascular inflammation and increased blood pressure, favoring the development of several cardiovascular complications, including hypertension.

Keywords

References

Circ Res. 2011 May 27;108(11):1358-66 [PMID: 21493895]
JAMA Cardiol. 2020 Nov 01;5(11):1265-1273 [PMID: 32730619]
mBio. 2014 Feb 25;5(2):e00856-14 [PMID: 24570368]
Cell. 2020 Apr 16;181(2):281-292.e6 [PMID: 32155444]
Intensive Care Med. 2020 Jun;46(6):1117-1120 [PMID: 32253448]
Int J Mol Sci. 2021 Jan 28;22(3): [PMID: 33525632]
J Clin Med. 2021 Jan 07;10(2): [PMID: 33430492]
Biochem Biophys Res Commun. 2012 Oct 5;426(4):486-91 [PMID: 22960172]
PLoS Pathog. 2011 Jun;7(6):e1002090 [PMID: 21695242]
Cannabis Cannabinoid Res. 2020 Sep 02;5(3):197-201 [PMID: 32923657]
Am J Hypertens. 2015 Jan;28(1):135-42 [PMID: 24906486]
J Exp Med. 2008 Feb 18;205(2):361-72 [PMID: 18227220]
Int J Infect Dis. 2020 May;94:91-95 [PMID: 32173574]
Eur Respir J. 2020 May 14;55(5): [PMID: 32217650]
Cell. 2020 Apr 16;181(2):271-280.e8 [PMID: 32142651]
Int J Mol Sci. 2020 Dec 06;21(23): [PMID: 33291346]
PLoS Pathog. 2009 May;5(5):e1000427 [PMID: 19436702]
Life Sci. 2020 Dec 1;262:118436 [PMID: 32950570]
Open Biol. 2020 Sep;10(9):200160 [PMID: 32961074]
N Engl J Med. 2020 Feb 20;382(8):727-733 [PMID: 31978945]
Am J Respir Crit Care Med. 2005 Dec 15;172(12):1485-6 [PMID: 16444822]
J Allergy Clin Immunol. 2020 Jul;146(1):110-118 [PMID: 32294485]
Biochim Biophys Acta Mol Basis Dis. 2020 Mar 1;1866(3):165606 [PMID: 31740405]
Am J Physiol Heart Circ Physiol. 2020 May 1;318(5):H1084-H1090 [PMID: 32228252]
Circ Res. 2016 Apr 15;118(8):1313-26 [PMID: 27081112]
Hypertension. 2001 Sep;38(3):399-403 [PMID: 11566912]
Proc Natl Acad Sci U S A. 2020 May 26;117(21):11727-11734 [PMID: 32376634]
Adv Virus Res. 2011;81:85-164 [PMID: 22094080]
Eur J Case Rep Intern Med. 2020 Jun 17;7(7):001784 [PMID: 32665939]
Clin Sci (Lond). 2020 Jan 31;134(2):303-313 [PMID: 31998948]
J Biol Chem. 2003 May 9;278(19):16713-9 [PMID: 12609980]
Am J Physiol Heart Circ Physiol. 2019 May 1;316(5):H1027-H1038 [PMID: 30793936]
J Biol Chem. 2016 Jul 15;291(29):15093-107 [PMID: 27226571]
Proc Natl Acad Sci U S A. 2021 Apr 20;118(16): [PMID: 33811184]
Biomed Res Int. 2014;2014:406960 [PMID: 25136585]
Trends Pharmacol Sci. 2004 Jun;25(6):291-4 [PMID: 15165741]
Nat Med. 2020 May;26(5):681-687 [PMID: 32327758]
Biochem Pharmacol. 2009 Sep 15;78(6):539-52 [PMID: 19413999]
Sci Rep. 2020 Dec 10;10(1):21613 [PMID: 33303885]

Grants

  1. P01 HL134604/NHLBI NIH HHS
  2. U24 DK076169/NIDDK NIH HHS
  3. U24 DK115255/NIDDK NIH HHS

MeSH Term

Animals
COVID-19
Humans
Hypertension
Mice
RNA, Double-Stranded
SARS-CoV-2
Signal Transduction
Toll-Like Receptor 3

Chemicals

RNA, Double-Stranded
Toll-Like Receptor 3